REET 在甲状腺癌中的核心作用。
Central role of RET in thyroid cancer.
机构信息
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universita' degli Studi di Napoli Federico II, 80131 Napoli, Italy.
出版信息
Cold Spring Harb Perspect Biol. 2013 Dec 1;5(12):a009233. doi: 10.1101/cshperspect.a009233.
Abstract
RET (rearranged during transfection) is a receptor tyrosine kinase involved in the development of neural crest derived cell lineages, kidney, and male germ cells. Different human cancers, including papillary and medullary thyroid carcinomas, lung adenocarcinomas, and myeloproliferative disorders display gain-of-function mutations in RET. Accordingly, RET protein has become a promising molecular target for cancer treatment.
摘要
RET（转染重排）是一种受体酪氨酸激酶，参与神经嵴衍生细胞谱系、肾脏和男性生殖细胞的发育。不同的人类癌症，包括甲状腺乳头状癌和髓样癌、肺腺癌和骨髓增生性疾病，都显示出 RET 的功能获得性突变。因此，RET 蛋白已成为癌症治疗有前途的分子靶标。
相似文献
1
Central role of RET in thyroid cancer.REET 在甲状腺癌中的核心作用。
Cold Spring Harb Perspect Biol. 2013 Dec 1;5(12):a009233. doi: 10.1101/cshperspect.a009233.
2
Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.酪氨酸激酶抑制剂用于治疗甲状腺髓样癌
Recent Results Cancer Res. 2015;204:227-49. doi: 10.1007/978-3-319-22542-5_11.
3
Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.甲状腺髓样癌中耐药克隆的出现可能无法通过后续的挽救性转染期间高度选择性重排抑制剂治疗得到挽救。
Thyroid. 2021 Feb;31(2):332-333. doi: 10.1089/thy.2020.0449. Epub 2020 Aug 4.
4
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.RET 蛋白酪氨酸激酶抑制剂在 RET 驱动型甲状腺癌和肺癌治疗中的作用。
Pharmacol Res. 2018 Feb;128:1-17. doi: 10.1016/j.phrs.2017.12.021. Epub 2017 Dec 25.
5
[RET Gene Alterations in Thyroid Cancer-Towards Treatment with Selective RET Inhibitors].[甲状腺癌中的RET基因改变——迈向选择性RET抑制剂治疗]
Gan To Kagaku Ryoho. 2023 May;50(5):611-614.
6
Precision Targeted Therapy with BLU-667 for -Driven Cancers.BLU-667 精准靶向治疗 - 驱动型癌症。
Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.
7
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.泊那替尼（AP24534）是一种新型有效的致癌 RET 突变体抑制剂，与甲状腺癌相关。
J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22.
8
Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.RET 原癌基因突变的多样性及其在甲状腺髓样癌中的致癌机制。
Crit Rev Clin Lab Sci. 2016 Aug;53(4):217-27. doi: 10.3109/10408363.2015.1129529. Epub 2016 Jan 27.
9
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.挑战临床无反应性甲状腺髓样癌：新型RET抑制剂的发现及药理活性
Eur J Med Chem. 2018 Apr 25;150:491-505. doi: 10.1016/j.ejmech.2018.02.080. Epub 2018 Mar 2.
10
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.基于椭圆屈碱衍生物的用于治疗甲状腺髓样癌的有效 RET 转录抑制剂的展示。
Int J Oncol. 2017 Jul;51(1):145-157. doi: 10.3892/ijo.2017.3994. Epub 2017 May 11.
引用本文的文献
1
Targeting the Purinergic Axis with Phenolic Compounds to Disrupt the Oxidative-Inflammatory Cycle in Thyroid Cancer.用酚类化合物靶向嘌呤能轴以破坏甲状腺癌中的氧化-炎症循环。
Int J Mol Sci. 2025 Aug 31;26(17):8474. doi: 10.3390/ijms26178474.
2
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.甲状腺癌：流行病学、分类、危险因素、诊断和预后标志物以及当前的治疗策略。
Int J Mol Sci. 2025 May 28;26(11):5173. doi: 10.3390/ijms26115173.
3
Thyroid C-Cell Biology and Oncogenic Transformation.甲状腺C细胞生物学与致癌转化
Recent Results Cancer Res. 2025;223:51-91. doi: 10.1007/978-3-031-80396-3_3.
4
Celastrol promotes apoptotic cell death in thyroid cancer cells through a caspases-dependent pathway.雷公藤红素通过半胱天冬酶依赖性途径促进甲状腺癌细胞的凋亡性细胞死亡。
Thyroid Res. 2025 Feb 26;18(1):9. doi: 10.1186/s13044-024-00222-7.
5
Medullary Thyroid Carcinoma and Clinical Outcomes in Heterozygous Carriers of the K666N Germline Pathogenic Variant.K666N种系致病变体杂合携带者中的甲状腺髓样癌及临床结局
JCEM Case Rep. 2025 Feb 17;3(3):luaf002. doi: 10.1210/jcemcr/luaf002. eCollection 2025 Mar.
6
Thyroid Carcinoma Glycoproteins Express Altered -Glycans with 3-O-Sulfated Galactose Residues.甲状腺癌糖蛋白表达带有3-O-硫酸化半乳糖残基的异常聚糖。
Biomolecules. 2024 Nov 21;14(12):1482. doi: 10.3390/biom14121482.
7
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.塞尔帕替尼与线粒体靶向抗氧化剂MitoQ联合使用可有效抑制RET突变型甲状腺癌。
NPJ Precis Oncol. 2024 Feb 20;8(1):39. doi: 10.1038/s41698-024-00536-7.
8
Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.增强子激活的 RET 赋予 KMT2A 重排的急性髓系白血病对氧化应激的保护作用。
Cancer Sci. 2024 Mar;115(3):963-973. doi: 10.1111/cas.16069. Epub 2024 Jan 16.
9
An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases.肾细胞癌全身靶向治疗概述，重点关注转移性肾细胞癌和脑转移
Curr Issues Mol Biol. 2023 Sep 21;45(9):7680-7704. doi: 10.3390/cimb45090485.
10
-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.- 改变的癌症——肿瘤非特异性生物学、诊断及靶向治疗活性综述
Cancers (Basel). 2023 Aug 17;15(16):4146. doi: 10.3390/cancers15164146.
本文引用的文献
1
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.卡博替尼治疗 RET 融合阳性肺腺癌患者的疗效。
Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.
2
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.泊那替尼（AP24534）是一种新型有效的致癌 RET 突变体抑制剂，与甲状腺癌相关。
J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22.
3
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.RET 融合定义了一种独特的非小细胞肺癌的分子和临床病理亚型。
J Clin Oncol. 2012 Dec 10;30(35):4352-9. doi: 10.1200/JCO.2012.44.1477. Epub 2012 Nov 13.
4
RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.RET 融合基因与慢性粒单核细胞白血病相关，并增强单核细胞分化。
Leukemia. 2012 Nov;26(11):2384-9. doi: 10.1038/leu.2012.109. Epub 2012 Apr 19.
5
Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers.从不吸烟者的“全阴性”肺癌中外显子阵列分析鉴定RET基因融合
Cell Res. 2012 May;22(5):928-31. doi: 10.1038/cr.2012.27. Epub 2012 Feb 21.
6
KIF5B-RET fusions in lung adenocarcinoma.肺腺癌中的 KIF5B-RET 融合。
Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.
7
RET, ROS1 and ALK fusions in lung cancer.肺癌中的 RET、ROS1 和 ALK 融合。
Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.
8
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.鉴定结直肠癌和肺癌活检组织中的新型 ALK 和 RET 基因融合。
Nat Med. 2012 Feb 12;18(3):382-4. doi: 10.1038/nm.2673.
9
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.全基因组和转录组测序揭示肺腺癌中存在一个转化的 KIF5B 和 RET 基因融合。
Genome Res. 2012 Mar;22(3):436-45. doi: 10.1101/gr.133645.111. Epub 2011 Dec 22.
10
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.凡德他尼治疗局部晚期或转移性甲状腺髓样癌患者的疗效：一项随机、双盲 III 期临床试验。
J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24.
Zotero 插件